BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

34 related articles for article (PubMed ID: 24085358)

  • 21. Analysis of CYP3A4*1B and CYP3A5*3 polymorphisms in population of Bosnia and Herzegovina.
    Semiz S; Dujić T; Ostanek B; Prnjavorac B; Bego T; Malenica M; Mlinar B; Marc J; Causević A
    Med Glas (Zenica); 2011 Feb; 8(1):84-9. PubMed ID: 21263403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients.
    Żochowska D; Wyzgał J; Pączek L
    Ann Transplant; 2012; 17(3):36-44. PubMed ID: 23018254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of CYP3A4, CYP3A5 polymorphisms with lung cancer risk in Bangladeshi population.
    Islam MS; Mostofa AG; Ahmed MU; Bin Sayeed MS; Hassan MR; Hasnat A
    Tumour Biol; 2014 Feb; 35(2):1671-8. PubMed ID: 24085358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic contribution to variable human CYP3A-mediated metabolism.
    Lamba JK; Lin YS; Schuetz EG; Thummel KE
    Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CYP3A4*1B polymorphism and cancer risk: a HuGE review and meta-analysis.
    Zhou LP; Yao F; Luan H; Wang YL; Dong XH; Zhou WW; Wang QH
    Tumour Biol; 2013 Apr; 34(2):649-60. PubMed ID: 23179402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CYP3A4 polymorphisms--potential risk factors for breast and prostate cancer: a HuGE review.
    Keshava C; McCanlies EC; Weston A
    Am J Epidemiol; 2004 Nov; 160(9):825-41. PubMed ID: 15496535
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population?
    Maslub MG; Radwan MA; Daud NAA; Sha'aban A
    Eur J Med Res; 2023 Sep; 28(1):381. PubMed ID: 37759317
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 30.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 31.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 32.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.